Consolidated Statements of Changes in Shareholders' Deficit - USD ($) $ in Millions		Total	Cumulative effect adjustment	Common Stock	Additional Paid-in Capital	Retained Earnings	Retained Earnings Cumulative effect adjustment	Accumulated Other Comprehensive Loss	Treasury Stock	Noncontrolling Interest
Beginning balance (in shares) at Dec. 31, 2018				761,800,000					319,400,000
Beginning balance at Dec. 31, 2018		$ (896.8)		$ 190.3	$ 2,303.6	$ 2,234.3		$ (1,030.4)	$ (4,602.3)	$ 7.7
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income		(33.5)				(32.7)				(0.8)
Other comprehensive (loss) income		(3.9)						(4.0)		0.1
Dividends accrued - Series C convertible preferred stock		(6.2)				(6.2)
Exercise/ vesting/ expense of share-based compensation (in shares)				1,300,000
Exercise/ vesting/ expense of share-based compensation		(1.2)		$ 0.3	(1.5)
Purchases and sales of noncontrolling interests, net of dividends paid of $0.0		0.1								0.1
Ending balance (in shares) at Mar. 31, 2019				763,100,000					319,400,000
Ending balance at Mar. 31, 2019		(941.5)		$ 190.6	2,302.1	2,195.4		(1,034.4)	$ (4,602.3)	7.1
Beginning balance (in shares) at Dec. 31, 2018				761,800,000					319,400,000
Beginning balance at Dec. 31, 2018		(896.8)		$ 190.3	2,303.6	2,234.3		(1,030.4)	$ (4,602.3)	7.7
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income		54.0
Other comprehensive (loss) income		(19.3)
Ending balance (in shares) at Sep. 30, 2019				763,400,000					319,900,000
Ending balance at Sep. 30, 2019		(875.2)		$ 190.4	2,310.5	2,270.0		(1,049.7)	$ (4,603.3)	6.9
Beginning balance (in shares) at Dec. 31, 2018				761,800,000					319,400,000
Beginning balance at Dec. 31, 2018		(896.8)		$ 190.3	2,303.6	2,234.3		(1,030.4)	$ (4,602.3)	7.7
Ending balance (in shares) at Dec. 31, 2019				770,000,000.0					319,900,000
Ending balance at Dec. 31, 2019		$ (983.8)	$ (2.0)	$ 192.6	2,321.2	2,138.9	$ (2.0)	(1,040.0)	$ (4,603.3)	6.8
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible List]		us-gaap:AccountingStandardsUpdate201613Member
Beginning balance (in shares) at Mar. 31, 2019				763,100,000					319,400,000
Beginning balance at Mar. 31, 2019		$ (941.5)		$ 190.6	2,302.1	2,195.4		(1,034.4)	$ (4,602.3)	7.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income		(19.1)				(19.5)				0.4
Other comprehensive (loss) income		5.5						5.5
Dividends accrued - Series C convertible preferred stock		(6.4)				(6.4)
Exercise/ vesting/ expense of share-based compensation		5.4			5.4
Repurchase of common stock (in shares)				100,000					500,000
Repurchase of common stock		(1.0)		$ 0.1					$ (1.0)
Purchases and sales of noncontrolling interests, net of dividends paid of $0.0		(0.3)								(0.3)
Ending balance (in shares) at Jun. 30, 2019				763,200,000					319,900,000
Ending balance at Jun. 30, 2019		(957.3)		$ 190.7	2,307.5	2,169.5		(1,028.9)	$ (4,603.3)	7.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income		106.6				106.9				(0.3)
Other comprehensive (loss) income		(20.8)						(20.8)
Dividends accrued - Series C convertible preferred stock		(6.4)				(6.4)
Exercise/ vesting/ expense of share-based compensation (in shares)				300,000
Exercise/ vesting/ expense of share-based compensation		3.3		$ 0.3	3.0
Repurchase of common stock (in shares)				(100,000)
Repurchase of common stock		(0.6)		$ (0.6)
Ending balance (in shares) at Sep. 30, 2019				763,400,000					319,900,000
Ending balance at Sep. 30, 2019		$ (875.2)		$ 190.4	2,310.5	2,270.0		(1,049.7)	$ (4,603.3)	6.9
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock (in dollars per share)		$ 0.25
Stock, shares authorized (in shares)		1,525,000,000
Common stock, authorized (in shares)		1,500,000,000
Preferred stock, authorized (in shares)		25,000,000
Preferred stock, par value (in dollars per share)		$ 1.00
Beginning balance (in shares) at Dec. 31, 2019				770,000,000.0					319,900,000
Beginning balance at Dec. 31, 2019		$ (983.8)	(2.0)	$ 192.6	2,321.2	2,138.9	(2.0)	(1,040.0)	$ (4,603.3)	6.8
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income		(171.9)				(171.0)				(0.9)
Other comprehensive (loss) income		(104.5)						(104.3)		(0.2)
Conversion of Series C convertible preferred stock (in shares)	[1]								(87,000,000.0)
Conversion of Series C convertible preferred stock	[1]	486.8				(710.8)			$ 1,197.6
Exercise/ vesting/ expense of share-based compensation		(9.9)		$ (0.2)	(9.7)
Exchange of common stock (in shares)	[2]			(770,000,000.0)					(232,900,000)
Exchange of common stock	[2]			$ (192.4)	(1,788.1)	(1,425.2)			$ 3,405.7
Ending balance (in shares) at Mar. 31, 2020	[3]			0					0
Ending balance at Mar. 31, 2020	[3]	(785.3)		$ 0.0	523.4	(170.1)		(1,144.3)	$ 0.0	5.7
Beginning balance (in shares) at Dec. 31, 2019				770,000,000.0					319,900,000
Beginning balance at Dec. 31, 2019		(983.8)	$ (2.0)	$ 192.6	2,321.2	2,138.9	$ (2.0)	(1,040.0)	$ (4,603.3)	6.8
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income		(298.9)
Other comprehensive (loss) income		(126.9)
Ending balance (in shares) at Sep. 30, 2020				0					0
Ending balance at Sep. 30, 2020		$ (929.0)		$ 0.0	527.7	(294.3)		(1,166.9)	$ 0.0	4.5
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible List]		us-gaap:AccountingStandardsUpdate201613Member
Beginning balance (in shares) at Mar. 31, 2020	[3]			0					0
Beginning balance at Mar. 31, 2020	[3]	$ (785.3)		$ 0.0	523.4	(170.1)		(1,144.3)	$ 0.0	5.7
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income		(93.5)				(92.8)				(0.7)
Other comprehensive (loss) income		(1.5)						(1.5)
Exercise/ vesting/ expense of share-based compensation		0.8			0.8
Ending balance (in shares) at Jun. 30, 2020				0					0
Ending balance at Jun. 30, 2020		(879.5)		$ 0.0	524.2	(262.9)		(1,145.8)	$ 0.0	5.0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income		(33.5)				(32.8)				(0.7)
Gain on common control transaction		1.4				1.4
Other comprehensive (loss) income		(20.9)						(21.1)		0.2
Exercise/ vesting/ expense of share-based compensation		3.5			3.5
Ending balance (in shares) at Sep. 30, 2020				0					0
Ending balance at Sep. 30, 2020		$ (929.0)		$ 0.0	$ 527.7	$ (294.3)		$ (1,166.9)	$ 0.0	$ 4.5
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock (in dollars per share)		$ 0.01
Common stock shares outstanding (in shares)		101.34

[1] On December 30, 2019, an affiliate of Cerberus Capital Management, L.P. ("Cerberus") elected to convert 435,000 shares of Series C Preferred Stock into 87,000,000 shares of the Company’s common stock, par value U.S.$0.25 per share, conditioned on the Conversion Condition (as defined below). See Note 12, Series C Convertible Preferred Stock.

[2] In January 2020, subsequent to the Transaction, the Company restated its certificate of incorporation to effect a change in capitalization of the Company by changing the number of authorized shares of stock from 1,525,000,000 shares (of which (i) 1,500,000,000 shares, par value $0.25 per share, were common stock and (ii) 25,000,000 shares, par value $1.00 per share, were preferred stock) to 1,000 shares of common stock, par value $0.01 per share. As a result of the Merger, all of the issued and outstanding common stock of the Company, being 550,890,788, were canceled and converted. See Note 18, Mergers     with Natura Cosméticos S.A.,.

[3] The number of shares of Common Stock (par value $0.01 per share) outstanding at September 30, 2020 was 101.34.